Following a strong post-election rally, equities, particularly small caps, experienced a pullback this quarter. Momentum faded among many recent leaders, including the “Magnificent Seven,” as sentiment-driven growth stocks lagged behind value. This reset appeared healthy, and arguably overdue, after several years of strong post-pandemic gains and economic resilience.
Adding to the uncertainty, the new administration’s early policy moves have raised fresh questions, while the Federal Reserve has shifted into a holding pattern after last year’s rate cuts. Together, these factors have contributed to a more cautious tone in markets.
Earnings expectations have begun to moderate and may soften further, raising questions about whether small caps can regain leadership over large caps in 2025. As a result, small-cap valuations have compressed more meaningfully creating potential opportunities for selective investors as sentiment resets and longer-term fundamentals come back into focus.
Whether this quarter’s pullback proves to be a temporary pause, or the start of a more sustained downturn remains to be seen. Either way, staying patient and opportunistic through periods of volatility remains essential.
Discussion of First Quarter Performance and Positions
During the quarter, the Shaker Small Cap Growth Strategy outperformed its benchmark in a challenging market environment, posting a return of -6.5% versus -11.1% for the benchmark.
Healthcare and consumer staples stood out as bright spots, delivering positive absolute returns. On a relative basis, the strategy outperformed in all sectors except industrials and financials, with especially strong contributions from consumer staples and consumer discretionary stocks driving much of the outperformance.
Top Contributors
Halozyme Therapeutics (HALO) – HALO, a biotech company specializing in subcutaneous drug delivery, benefited from multiple regulatory approvals and favorable headlines during the quarter, supporting momentum.
Sprouts Farmers Market (SFM) – A top contributor for the fifth straight quarter, SFM continues to grow as one of the country’s fastest-expanding grocers. With shares up meaningfully, the portfolio trimmed its position to lock in gains.
Corcept Therapeutics (CORT) – Recently initiated, CORT develops treatments for hypercortisolism and related conditions. Its lead drug earned FDA approval for oncology use, expanding its potential addressable market.
Sportradar Group (SRAD) – Added in late 2024, SRAD is a global leader in real-time sports data and analytics, serving both media and betting industries as demand for live content and integrity services grows.
Casey’s General Stores (CASY) – CASY, a convenience store and fuel retailer across the Midwest and Southeast, continues to deliver steady expansion and operational resilience in a highly competitive space.
Top Detractors
Zebra Technologies (ZBRA) – A leader in automatic identification and data capture technology, ZBRA lowered its 2025 guidance amid rising geopolitical uncertainty, which weighed on sentiment.
Agilysys (AGYS) – This hospitality-focused IT software provider saw softness in point-of-sale product sales, a key growth driver. Despite the shortfall, the company’s long-term growth narrative remains compelling.
Comfort Systems USA (FIX) – FIX continues to benefit from increased AI-related infrastructure demand, but tariff pressures are squeezing margins and dragging on recent performance.
Boot Barn Holdings (BOOT) – BOOT, which operates a nationwide network of western wear stores, has faced investor concern around margin pressure tied to tariff risk in Mexico and China.
Napco Security Systems (NSSC) – A second straight quarter of underwhelming sales performance from this security tech firm has kept pressure on the stock despite strong underlying industry demand.
Changes in the Portfolio
During the quarter, we added 13 new positions and exited eight, while also making selective trims and additions across the portfolio. Nearly half of the new additions came from the healthcare sector, where we had previously been underweight relative to the benchmark.
One notable addition was Merit Medical Systems (MMSI), a global medical device company with a broad product portfolio. A key catalyst is the FDA approval of WRAPSODY, a vascular access device designed to improve outcomes for dialysis patients. Competing with Gore’s Viabahn and Becton Dickinson’s Covera, WRAPSODY addresses a $600 million U.S. market and is expected to drive incremental growth in revenue and earnings.
We also addressed our underweight in technology by initiating several new positions, including Opera Ltd. (OPRA), a Norwegian-based browser company known for its user-focused features and strong customization. With a three-year sales CAGR above 20%, we believe OPRA is well-positioned for continued growth.
On the sell side, exits were driven by a mix of macro and company-specific factors, including policy shifts, tariff exposure, and deteriorating fundamentals. One example was Kirby Corp. (KEX), a long-time holding that benefited from post-COVID demand normalization but has since shown slowing momentum. We redeployed capital into opportunities with stronger forward outlooks.